Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Other Non-current Assets
Long-term assets not reported separately.
Septerna, Inc.NASDAQ: SEPN
Other Non-current Assets · Q3 FY2026 · quarter ended Sep 2026
Other non-current assets rises 6190.8% from a year ago
Other non-current assets stood at $88.45M at the end of Q3 FY2026, up 6190.8% from a year earlier and down 39.6% from the prior quarter. Over 3 fiscal years it compounded at +421.4% a year.
Context
- Other non-current assets amounted to 14.3% of total assets at the end of Q3 FY2026, up 14.0 pp from a year earlier.
- Other non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +6190.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 159.29M USD
- Year-over-year change
- +13491.3%
- 3-year CAGR
- +421.4%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 159.29M | +13491.3% |
| FY2024 | 2024-12-31 | 1.17M | +17.0% |
| FY2023 | 2023-12-31 | 1M | -10.9% |
| FY2022 | 2022-12-31 | 1.12M | — |
Other Non-current Assets vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's Sep 2026 other non-current assets of $88.45M is the 2nd highest of the 7 companies compared; the peer median is $2.83M.
- Its year-over-year change of +6190.8% is the highest of 5, against a peer median of +230.3%.
- Other non-current assets amounts to 14.3% of total assets for SEPN, versus a peer median of 0.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
KLRAKailera Therapeutics, Inc. | Jun 2026 | $270.6M | — | — | 22.3% |
SEPNSepterna, Inc. | Sep 2026 | $88.45M | +6190.8% | +421.4% | 14.3% |
| Jun 2026 | $41M | +561.0% | -40.8% | 2.9% | |
| Mar 2026 | $5.41M | +66.6% | +44.5% | 1.3% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $247K | +394.0% | +108.9% | 0.0% |
| Mar 2026 | $5K | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding SEPN) | $2.83M | +230.3% | +44.5% | 0.7% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.